Amneal Pharmaceuticals, Inc. AMRX
19.87 USD -0.34 (-1.66%)
Nov 4, 2026, 2:14 PM EST
19.02 Day range 20.55
11.15 52-week range 21.68
- YTD
- +57.73%
- 1 year
- +75.10%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.43 +17.9% upside
Now 19.87
- Target (low)
- 20.00
- Target (mean)
- 23.43
- Target (high)
- 27.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.22276 | 0.18 – 0.24 | 0.21 | +6.1% | 825.18M | +1.3% | 7 |
| Next quarter | 0.25147 | 0.23 – 0.26534 | 0.27 | -6.9% | 774.61M | +7.2% | 5 |
| Current year | 1.03 | 0.978 – 1.05 | 0.83 | +24.1% | 3.16B | +4.7% | 7 |
| Next year | 1.21 | 1.08 – 1.31 | 1.03 | +17.1% | 3.46B | +9.4% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 23, 2026 | Oppenheimer | Initiated | — | Outperform |
| Sep 17, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | Initiated | — | Outperform |
| Aug 3, 2026 | UBS | Maintained | Buy | Buy |
| Jul 15, 2026 | UBS | Maintained | Buy | Buy |
| May 20, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 17, 2026 | UBS | Initiated | — | Buy |
| Mar 2, 2026 | Truist Securities | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Oct 31, 2025 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 3, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 24, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Nov 11, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 2, 2024 | Truist Securities | Maintained | Buy | Buy |
| Sep 6, 2024 | JP Morgan | Upgrade | Underweight | Neutral |
| Aug 13, 2024 | Barclays | Maintained | Overweight | Overweight |
| Aug 12, 2024 | Truist Securities | Maintained | Buy | Buy |
| May 6, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| May 6, 2024 | Truist Securities | Reiterated | Buy | Buy |
| Mar 21, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 4, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 29, 2024 | Barclays | Maintained | Overweight | Overweight |
| Nov 8, 2023 | Truist Securities | Maintained | Buy | Buy |
| Sep 6, 2023 | Truist Securities | Reiterated | Buy | Buy |
| Aug 7, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 7, 2023 | Truist Securities | Maintained | Buy | Buy |
| Aug 7, 2023 | Barclays | Maintained | Overweight | Overweight |
| May 8, 2023 | Piper Sandler | Maintained | — | Overweight |
